As of June 21, 2025, Pandion Therapeutics Inc (PAND) reports a Net Margin of -2262.36%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Comparing Pandion Therapeutics Inc's Net Margin to Peers
To better understand Pandion Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Pandion Therapeutics Inc (PAND) | -2262.36% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Krystal Biotech Inc (KRYS) | 30.69% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Pandion Therapeutics Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.